In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function - Nov 7, 2010
Links shared publicly online about this topic.
- 744total visits
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function - Nov 7, 2010
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function - Nov 7, 2010
View full resource at pfizer.mediaroom.com
Tags: Arthritis, Rheumatoid Arthritis, Phase 3 Clinical Trial
Most Recently Shared on November 7, 2010 at 10:08 pm By:
Press Release: In First Phase 3 Trial...http://bit.ly/c9aVVz
Advertisement
